Understanding how mutations in ZFP36L2 affect colorectal cancer progression and immune response
Official title: Dissecting the Functional Consequences of Mutations in ZFP36L2 on Tumor Progression and Inflammation in the Tumor Immune Microenvironment of Colorectal Cancer
Funded at Weill Medical Coll of Cornell Univ · NIH-10996700 · Data updated 2026-11-12
This study is looking at how changes in a specific gene called ZFP36L2 might affect the growth of colorectal cancer and the way the immune system interacts with these tumors, with the hope of finding better treatment options for patients whose cancer doesn't respond well to current therapies.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $53,974 |
| NIH project number | 1F30CA288018-01A1 |
| Project ID | NIH-10996700 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with microsatellite stable (MSS) colorectal cancer, particularly those with advanced disease.
✕Less likely to help
Patients with microsatellite unstable (MSI) colorectal cancer may not benefit from this research as they typically respond better to existing immunotherapies.
What this research studies
This research investigates the role of ZFP36L2 mutations in colorectal cancer (CRC) and how these mutations influence tumor progression and the immune environment. By using advanced mouse models, the study aims to explore how the loss of ZFP36L2 function can lead to increased immune cell infiltration in tumors that typically do not respond well to current immunotherapies. The goal is to identify new targets and biomarkers that could improve treatment options for patients with microsatellite stable (MSS) colorectal cancer.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance the effectiveness of immunotherapy for a larger group of colorectal cancer patients.
How similar studies have gone: Previous research has shown promising results in targeting immune responses in colorectal cancer, but this specific approach focusing on ZFP36L2 mutations is relatively novel.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Luckett, Kathleen — Weill Medical Coll of Cornell Univ
- Study coordinator: Luckett, Kathleen
Related research
Other NIH-funded projects on the same topics.
-
Improving colorectal cancer screening and follow-up care.
This study is working to help more people get screened for colorectal cancer and receive the follow-up care they need, especially those who haven't been screened much before, so that everyone can have better access to important health checks and improve their overall health.
-
Colorectal cancer prognosis through a broad, collaborative study
A large, multi-center study follows people newly diagnosed with colorectal cancer to find biomarkers and patterns that predict outcomes and guide future care.
-
Ceramides and how they affect metabolism and colorectal cancer in adults
A study in adults with obesity-related health issues will explore how a fat-related molecule called ceramide influences metabolic problems and colorectal cancer risk.
-
Automated point-of-care DNA methylation test for colorectal cancer in LMICs
A fast, affordable blood test using DNA markers to help identify people at higher risk of colorectal cancer in low- and middle-income countries.
-
Rewiring Colorectal Cancer to Harness Therapeutic Hyperactivation
A Yale team is exploring brain-storming new ways to treat colorectal cancer by safely boosting certain cancer signaling pathways to kill cancer cells and by reshaping cancer cell states to improve responses to existing therapies.
-
Comparative modeling to guide colorectal cancer screening and care
A researcher team will use computer models to study how access to care, risk, and new screening options affect colorectal cancer outcomes and costs for adults in the US.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.